PREDICTIVE AND DIAGNOSTIC ROLE OF CIRCULATING GOLGI PROTEIN-73 AND GLYPICAN-3 PROTEIN FOR CHRONIC VIRAL HEPATITIS ASSOCIATED HEPATOCELLULAR CARCINOMA | ||
| ALEXMED ePosters | ||
| Article 1, Volume 6, Issue 2, April 2024, Pages 25-26 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2024.290679.1846 | ||
| Authors | ||
| Khalid Mahmoud Mohiedeen1; Mohamed Ahmed Kasem1; Nermeen Sherif Abdeen Ahmed1; Raghda Saad Zaghloul Taleb2; Mariam Abubakar Silas* 1 | ||
| 1Department of Tropical Medicine, Faculty of Medicine, Alexandria University | ||
| 2Department of Clinical & chemical Patholohy**, Faculty of Medicine, Alexandria University, Egypt | ||
| Abstract | ||
| INTRODUCTION Viral hepatitis, including Hepatitis B and C, is a significant global health challenge and a leading cause of mortality. In Egypt, approximately eight to ten million people are affected by these viruses, posing a serious public health threat. Chronic viral hepatitis can lead to severe complications, with cirrhosis often emerging after prolonged infection, increasing the risk of advanced liver diseases like hepatocellular carcinoma (HCC). Early detection of HCC is crucial, and current guidelines recommend biannual abdominal ultrasound and AFP testing for at-risk patients, though this method has limitations, including a sensitivity of only 63%.Identifying accurate biomarkers for HCC diagnosis is a priority. Glypican-3 (GPC3) and Golgi Protein 73 (GP73) have shown promise as potential biomarkers. GPC3 is highly expressed in HCC tumors and detectable in serum, while GP73 has demonstrated superior sensitivity to AFP. Despite their potential, further validation is necessary. AIM The present study aims to assess the serum level of GP73 and GPC-3 as diagnostic biomarkers for HCC in patients with viral hepatitis B and C liver cirrhosis. | ||
| Keywords | ||
| GOLGI PROTEIN-73; GLYPICAN-3; HEPATOCELLULAR CARCINOMA | ||
|
Supplementary Files
|
||
|
Statistics Article View: 78 |
||
